文献速递口腔修复与种植口腔颌面外科

间充质干细胞复合人工骨替代物行萎缩牙槽嵴骨增量的随机对照临床试验

Bone Augmentation of Atrophic Alveolar Ridges Using a Synthetic Bone Substitute With Mesenchymal Stem Cells: A Randomized, Controlled Clinical Trial.
PubMed 文献 · Clin Oral Implants Res · 2025-08-22

一项2期随机对照临床试验评估自体髂嵴来源间充质干细胞负载于可吸收合成骨替代物并覆盖非吸收膜,用于严重牙槽骨缺损三维骨增量的安全性与有效性,对照为自体骨块移植。48例患者随机分组(试验组36例、对照组12例),5个月CBCT显示试验组骨体积增益显著更优,平均差异480.01 mm3(p=0.032),两组不良事件与患者病痛均轻微,所有植入区均成功植入种植体。

要点

  • 细胞治疗组5个月骨体积增益显著优于自体骨块组,平均差异480.01 mm3(p=0.032)。
  • 试验组骨嵴体积平均变化1066.91 mm3,对照组586.9 mm3。
  • 两组不良事件与患者病痛均轻微,再生骨内种植体全部成功整合。

核心结论

  • 与自体骨块移植相比,自体髂嵴间充质干细胞复合合成骨替代物的细胞治疗在严重牙槽骨缺损三维骨增量中产生显著更大的骨体积增益。
  • 该细胞治疗不良事件与患者病痛轻微,再生骨内所有种植体均成功整合。

研究设计与样本

  • 2期随机对照临床试验,评估细胞治疗用于种植前严重牙槽骨缺损三维骨增量的安全性与有效性。
  • 试验组采用扩增的自体髂嵴来源间充质干细胞接种于合成生物可吸收骨替代物并覆盖非吸收膜,对照组采用自体骨块移植。
  • 共48例患者随机分组,试验组36例、对照组12例;其中7例因未达到扩增间充质干细胞最低数量要求而未能治疗。
  • 术后5个月通过CBCT比较骨体积变化,随后在再生区域植入种植体。

主要发现

  • 试验组骨体积增益显著大于对照组,平均差异480.01 mm3(p=0.032)。
  • 基线至5个月骨嵴体积平均变化试验组为1066.91 mm3,对照组为586.9 mm3。
  • 两组不良事件与患者病痛均轻微。
  • 再生骨内植入的种植体在两组均全部成功整合。

关键数值与推荐

  • 试验组36例、对照组12例,共48例随机;7例因未达到扩增间充质干细胞最低数量要求未能治疗。
  • 骨体积增益平均差异480.01 mm3(p=0.032),试验组优于对照组。
  • 骨嵴体积平均变化:试验组1066.91 mm3,对照组586.9 mm3(基线至5个月)。

临床怎么用

  • 对严重萎缩牙槽嵴需种植前骨增量者,可考虑自体髂嵴间充质干细胞复合合成骨替代物加非吸收膜的细胞治疗方案。
  • 需确保可获取足够数量的扩增间充质干细胞,否则患者可能无法接受该治疗。
  • 术后5个月CBCT评估骨体积后可植入种植体,两组种植体均成功整合。

局限性

  • 对照组样本量(12例)明显少于试验组(36例),组间样本量不均衡。
  • 7例患者因未达到扩增间充质干细胞最低数量要求而未能治疗,提示该细胞制备流程存在可行性限制。
  • 随访至种植体植入后整合成功,摘要未报告更长期种植体存活与骨增量稳定性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the efficacy and safety of a cell-based therapy for 3D bone augmentation of severe alveolar bone defects prior to dental implant placement. MATERIALS AND METHODS: A Phase 2 randomized controlled clinical trial evaluated the safety and efficacy of a cell therapy using expanded autologous iliac crest-derived mesenchymal cells seeded on a synthetic bioabsorbable bone substitute covered with a non-resorbable membrane. The control group received an autogenous bone block graft. After 5 months, CBCT scans were compared to measure the bone volume changes achieved after the regenerative surgery. Subsequently, dental implants were placed in the regenerated areas. RESULTS: A total of 48 patients were included and randomized (36 patients in the test group and 12 in the control group). However, seven patients did not reach the minimum required number of expanded MSCs and were therefore unable to be treated. The tested intervention demonstrated significantly greater gains in bone volume, with a mean difference of 480.01 mm3 (p = 0.032). Similarly, the mean change in bone crest volume from baseline to 5 months was notably higher in the test group (1066.91 mm3) compared to the control group (586.9 mm3). Adverse reactions and patient morbidity were minor in both groups. Implants were placed on the regenerated bone, and all were integrated successfully in both groups. CONCLUSIONS: The cell-based therapy resulted in significant changes in bone volume compared to the control treatment, enabling dental implants in all patients. The procedure was associated with minimal adverse effects and patient morbidity. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03373052, NCT04297813.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Sanz M, Gjerde C, Gjertsen BT, et al. Bone Augmentation of Atrophic Alveolar Ridges Using a Synthetic Bone Substitute With Mesenchymal Stem Cells: A Randomized, Controlled Clinical Trial. Clin Oral Implants Res. 2025. PMID: 40844304. doi:10.1111/clr.70025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。